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Abstract
Introduction and objectives. The study aimed at evaluating the impact of Hymenoptera venom allergy (HVA) in children 
and adolescents, on their parents’ QoL, taking into account their socio-demographic characteristics.  
Materials and method. The study sample consisted of 101 parents of children and adolescents aged 9–17 years, with a history 
of systemic reaction after insect sting who were referred for consultations in the tertiary level allergology department. The 
mean age of the parents was 39 years (SD=8.1; range 25–65 years); the majority were mothers (68%) and rural inhabitants 
(62%). QoL in parents of HVA children and adolescents was measured with the Parents of Children with Hymenoptera Venom 
Allergy Quality of Life Scale, a questionnaire covering 5 dimensions: anxiety, caution, limitations and discomfort, support 
provided to the child and feeling of safety, each measured on the scale ranging from 1 to 5. Independent predictors of QoL 
were estimated using the Generalized Linear Model.  
Results. Parents of urban children and adolescents treated with venom immunotherapy (VIT) up to 3 years (B=-1.37, 95CI= 
(-2.22;-0.53); p=0.001) and of rural children treated for more than 3 years (B=-0.94, 95CI=(-1.55;-0.33); p=0.003) reported 
lower anxiety than parents studied at diagnosis. In urban parents, individuals studied at VIT beginning reported a lower 
feeling of safety (B=-0.63, 95CI=(-1.11;-0.15); p=0.010); those studied up to 3 years of treatment reported a higher feeling of 
safety (B=0.64, 95CI=(0.11;1.16); p=0.018) than those studied at diagnosis. Contrariwise, in rural parents, those studied at the 
beginning of immunotherapy reported a higher feeling of safety than those studied at diagnosis (B=0.51, 95CI=(0.13;0.88); 
p=0.008).  
Conclusions. The longest VIT duration in children and adolescents with HVA is related to the decreased anxiety of their 
parents. Parent’s feeling of safety depends on the stage of treatment and place of residence.
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INTRODUCTION
Allergic reactions to Hymenoptera venom (HV) observed 
after insect stings (ISs) may be divided into large local 
reactions (LLRs) and systemic reactions (SRs), categorized 
into 4  grades according to Mueller’s classification [1]. 
Although only severe systemic reactions (grades 3 and 4) to 
ISs are potentially life-threatening, in spite of being almost 
10-times less frequent in children compared to adults (0.4–
0.8% vs. 3.0%), they still remain the second risk factor of 
anaphylaxis in the European population of children [2]. For 
this reason, Hymenoptera venom allergy (HVA) in children 
may impact not only on the patient’s health-related quality 
of life, as observed in many other diseases in all age groups, 
but also the quality of life (QoL) of the patient’s relatives, 
especially their parents [3–10].
OBJECTIVES
The aim of this study was to evaluate the impact of children’s 
and adolescents’ HVA on their parents’ QoL, to assess 
relationships between the dimensions of parents’ QoL, and 
their independent predictors in the context of both socio-
demographic and clinical characteristics (as hypothesized 
in Figure 1).
MATERIALS AND METHOD
Study sample. This is a cross-sectional study, which results 
originate from the analysis of data from 101 parents of 
children and adolescents aged 9–17 (named children in the 
following part of the text) with a history of SR after IS, 
referred to tertiary level consultations in 2010–2013. The 
mean parental age equalled 39 years (SD=8.1, range 25–65 
years); in the mentioned group mothers (68%) and rural 
inhabitants (62%) predominated. Written consent from 
the parents of HVA children was obtained. The study was 
approved by the local Bioethical Committee.
Measures. QoL in parents of HVA children and adolescents 
was measured with Parents of Children with Hymenoptera 
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Venom Allergy Quality of Life Scale (PoCHVAQoLS), the 
first scale designed for this purpose [11,12]. This is a self-
administered questionnaire consisting of 17 items covering 
5 dimensions, parallel to those measured by the Children 
with Hymenoptera Venom Allergy Quality of Life Scale 
(CHVAQoLS) in young HVA patients: anxiety, caution, 
limitations and discomfort, support provided to the child and 
feeling of safety [13, 14]. Each dimension was measured with 
3 items (except safety subscale and limitations and discomfort 
subscale, which consisted of 4 items), on a scale ranging 
from 1 to 5. In our previous study relieability for particular 
scales was estimated as 0.84 for anxiety, 0.75 – caution, 
0.82 – limitations and discomfort, 0.81 – support provided 
to the child and 0.75 for feeling of safety [11]. Reliability 
of the scale in the sample under study was estimated as 
0.91, 0.75, 0.79, 0.78 and 0.64 for respective subscales. Factor 
analysis conducted for the scale items revealed 4 factors with 
eigenvalues greater than 1, but a 5-factor solution provided 
a structure with a clearer interpretation: the first factor was 
defined by items from the anxiety and caution subscales, 
the second by 3 items from the discomfort and limitations 
subscale, the third by items from the support subscales, and 
the forth by 3 items from the safety subscale. One of these 
items loaded with similar strength on the 5th factor which was 
defined by one item from safety and one from the discomfort 
and limitations subscale. The questionnaire was filled-in 
during in-patient visits, after diagnostic or immunotherapy 
procedures.
In the regression models, male gender was treated as a 
reference category, both in the case of parents and children. 
Age, both of parents and their children, was treated as 
a continuous variable. Additionally, as parental age was 
involved in interaction terms in some regression models, it 
was centred around its mean value. Place of residence was 
analysed as a binary variable indicating rural inhabitants 
compared to urban inhabitants (reference category).
Parents were categorized according to SR severity in their 
child, which was coded 1–4, according to the grades of 
Mueller’s classification. Due to the small percentage of parents 
of the children with LLR, this category was aggregated with 
those with Mueller’s 1st grade and called altogether dermal 
reactors (reference category). Whereas parents of children 
with at least 2nd grade of SRs severity were aggregated into 
the second category [15].
Parents were divided into 4 categories, according to the 
moment at which their QoL was measured in the context of 
child’s stage of treatment: those studied at child’s diagnosis 
(reference category), those studied at the incremental dose 
of venom immunotherapy (VIT) of their children, those 
studied for up to 3 years of maintenance dose, and those 
studied for more than 3 years after beginning VIT. The 
period census was selected so that the 3-year period was the 
shortest recommended time for VIT, and additionally, the 
sizes of the 2 categories were similar.
QoL measurements were performed at different stages of 
medical procedures: parents studied at diagnosis of their 
children and at the beginning of VIT with incremental 
dose were studied irrespective of the season of the year, 
whereas children studied at different stages of VIT with 
maintenance dose were studied during regular outpatient 
visits in September or October (regarded as the high season 
of Hymenoptera activity – in this study referred to as ‘the 
season’). Accordingly, a binary variable was included as a 
confounder in the regression models, indicating parents 
studied outside the season.
Parents were classified with regard to culprit insects which 
caused SR in their children, as bee, wasp, or unidentified 
insect. The last category (reference group) included only 
parents studied at the diagnosis of their children.
Statistical analysis. Qualitative variables were described 
as counts (n) and percentages (%), whereas quantitative 
variables were described as means and standard deviations.
Factor analysis using the principal component method with 
Varimax rotation was used to investigate factor structure of 
the items constituting PoCHVAQoLS, and Cronbach alpha 
coefficient was used to estimate reliability of the scale.
To assess independent predictors of parents’ QoL, linear 
regression models were estimated using the Generalized 
Linear Model (GZLM) with identity linking function, and 
variables of normal distribution as dependents. Regression 
results were presented as raw regression coefficient B, 
respective 95% confidence intervals and respective p value. 
All 2-way interactions between variables in the model were 
tested.
Some variables represented nested effects, e.g. Mueller’s 
grade of a child’s anaphylactic reaction, stage of treatment 
and culprit insect, in the sense that dermal reactors, as well as 
an unidentified culprit insect, were observed only in parents 
studied at diagnosis of their children. In these variables, 
separation of the effects was not fully possible, they were 
therefore tested in separate models and the most significant 
was included in the final regression model.
Differences at p<0.05 were treated as statistically significant. 
IBM SPSS Statistics 21 for Windows statistical software was 
used.
RESULTS
Demographic characteristics of parents and clinical 
characteristics of their children. The parents were studied 
at different stages of the medical procedures undertaken 
with their children – mostly during diagnostic evaluation, 
to a lesser extent at the moment of VIT introduction and at 
different stages of the maintenance phase of VIT; among the 
urban-dwellers, there were no parents of children treated for 
Figure 1. Model of the hypothesized relationships between dimensions of QoL of 
parents of children and adolescents with HVA
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more than 3 years. In 50%, the parents were studied outside 
the season. The mean age of children of the studied parents 
was 10.4 years (SD 3.8), they were mostly boys (72%), and 
the majority of children of studied parents were sensitized 
to bee venom (B.v.), while in 20% of the entire study group 
(40% of parents studied at their children’s diagnosis), the 
type of insect was unidentified. There was a predominance 
of Mueller’s 2nd grade pre-diagnosis systemic reaction in 
children of studied parents, followed by 3rd and 4th SR (Tab. 1).
Quality of life. According to the classification suggested 
by the authors (1–1.79 – very low, 1.8–2.59 – low, 2.6–3.4 
– moderate, 3.41–4.2 – high, 4.21–5.0 – very high), in the 
parents of children with HVA, the levels of anxiety and 
safety as well as of limitations and discomfort may be treated 
as moderate. The level of caution and support provided to 
children may be treated as high (Tab. 2) [16].
Multivariate analysis. Due to a significant interaction 
between the stage of treatment and place of residence, the 
results of the regression model for anxiety were presented 
separately for urban and rural-dwelling parents. A significant 
interaction was observed in rural parents between their 
gender and age which showed that paternal anxiety decreased 
and maternal anxiety increased along with their age. The 
difference between the slopes of these relationships was 
significant. Parents of urban children and treated with VIT 
for up to 3 years, as well as parents of rural living children, 
but treated longer than 3 years, reported lower anxiety than 
the parents of children studied at diagnosis. A significant 
interaction also occurred in parents whose children were 
studied at the beginning of VIT – their anxiety increased 
with age significantly faster than in parents of diagnosed 
children, irrespective of place of residence. Additionally, 
in rural-dwelling parents studied at the beginning of VIT, 
anxiety decreased significantly faster, together with the 
child’s age, whereas in those studied up to 3 years of VIT, 
anxiety increased significantly faster, together with the 
child’s age, compared to the parents of children studied at 
diagnosis (Tab. 3).
Parental caution increased along with their increasing 
anxiety (B=0.72, 95%CI=(0.58; 0.85); p<0.001), but decreased 
slightly with the age of their children (B=-0.04, 95%CI= 
(-0.07;-0.01); p=0.049).
Limitations and discomfort of the parents were higher in 
those whose children were sensitized to wasp venom (B=0.63, 
95%CI=(0.22; 1.03); p=0.003) or to bee venom (B=0.56, 
95%CI=(0.18; 0.95); p=0.004) than in those whose children 
were stung by unidentified insects. The level of limitations 
and discomfort of the studied parents increased along with 
their anxiety (B=0.44, 95%CI=(0.23; 0.65); p<0.001) and 
caution (B=0.23, 95%CI=(0.01; 0.45); p=0.044).
Significant interaction between the parental gender and 
Mueller’s grade of their child’s SR indicates that in parents 
of children being dermal reactors only, mothers gave their 
children more support than the fathers (B=1.23, 95%CI=(1.04; 
2.88); p<0.001), but this difference was compensated in 
children with higher grades: (B=-1.74, 95%CI=(-2.82; -0.67); 
p=0.002) for 2nd grade, and (B=-1.44, 95%CI=(-2.51; -0.38); 
p=0.008) for Mueller’s 4th grade. For this reason, the results 
of the regression model were presented separately for fathers 
and mothers.
Among the fathers there was a significant interaction 
between their age and the evaluation of support in the context 
of season. This indicated that the level of provided support 
decreased together with the age of the parent only in those 
studied outside that season. Fathers of children with at least 
Mueller’s 2nd grade gave more support to their children than 
fathers of dermal reactors, whereas in mothers, there was 
no significant difference in the level of provided support 
in relation to grade of anaphylactic reaction. Parents of 
treated children provided them less support than parents 
of those diagnosed and those studied at the beginning of 
VIT; however, the only significant difference was observed 
between the mothers of children treated for more than 
3  years, compared to those studied at diagnosis. Support 
increased with an increase in the level of limitations and 
discomfort (Tab. 4).
Due to significant regression coefficients for the interaction 
between stage of treatment and place of residence, the results 
of the regression model for feeling of safety were presented 
separately for urban and rural-dwelling parents. In urban 
inhabitants, the parents of girls reported higher feeling of 
safety than parents of boys. In rural dwellers, the fathers 
of girls reported a lower level of this emotion than fathers 
of boys, whereas mothers of girls reported a higher level of 
feeling of safety than mothers of boys. Only in urban-living 
parents there occurred a significant decrease in the feeling of 
safety level related to an increase of the child’s age. Parents 
studied outside the season reported a lower level of feeling 
of safety; however, the difference was significant only in 
rural dwellers. In urban living parents, those studied at 
the beginning of VIT reported a lower feeling of safety, 
whereas those studied up to 3 years of treatment reported a 
higher level of this emotion than those studied at diagnosis. 
Contrariwise, in rural living parents, those studied at the 
Table 1. Clinical characteristics of children of studied parents
N %
Culprit insect Not identified 20 19.8
Wasp 37 36.6
Honey bee 44 43.6
Stage of treatment Diagnosis 48 47.5
VIT beginning 23 22.8
Up to 3 years of VIT 16 15.8
3 years of VIT or longer 14 13.9
Mueller’s grade of anaphylactic reaction before treatment
LLR or 1st 16 15.9
2nd 33 32.7
3rd 26 25.7
4th 26 25.7
Total 101 100
Table 2. Mean levels of QoL dimensions in studied parents of HVA children
Dimension mean SD No. of items
Anxiety 3.3 0.9 3
Caution 3.8 0.9 3
Limitations and discomfort 2.6 0.9 4
Support provided to children 3.8 0.8 3
Feeling of safety 3.2 0.7 4
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Table 3. Independent predictors of anxiety in parents of HVA children and adolescents with respect to their place of residence
Urban Rural
B 95% CI p B 95% CI p
Gender: F vs. M 0.15 -0.60 0.91 0.695 0.05 -0.38 0.47 0.824
Parent’s age -0.04 -0.16 0.07 0.491 -0.04 -0.08 0.00 0.063
Interaction between gender and parent’s age -0.02 -0.15 0.10 0.736 0.06 0.01 0.11 0.027
VIT beginning vs. diagnosis  -0.03 -0.93 0.86 0.943 0.09 -0.43 0.61 0.736
Up to 3 yrs of VIT vs. diagnosis -1.37 -2.22 -0.53 0.001 -0.31 -1.02 0.40 0.395
3 years of VIT or longer vs. diagnosis - - - - -0.94 -1.55 -0.33 0.003
Interaction between stage of treatment and parents’ age
VIT beginning by parent’s age 0.18 0.01 0.36 0.041 0.10 0.01 0.19 0.028
Up to 3 yrs of VIT by parent’s age 0.03 -0.17 0.24 0.757 0.02 -0.05 0.07 0.631
3 yrs of VIT or longer by parent’s age  - - - - 0.02 -0.06 0.10 0.629
Child’s age 0.05 -0.06 0.16 0.349 -0,02 -0.10 0.07 0.679
Interaction between stage of treatment and child’s age
VIT beginning by child’s age  -0.32 -0.85 0.21 0.236 -0.18 -0.33 -0.03 0.016
Up to 3 yrs of VIT by child’s age -0.19 -0.46 0.09 0.184 0.21 0.03 0.39 0.021
3 yrs of VIT or longer by child’s age  - - - - 0.00 -0.20 0.20 0.988
Constant 3.38 2.73 4.03 <0.001 3.38 2.93 3.83 <0.001
Table 4. Support provided to young HVA patients by their parents with respect to parents’ gender
Fathers Mothers
B 95% CI p B 95% CI p
Parent’s age 0.01 -0.02 0.04 0.440 0.00 -0.04 0.03 0.818
Studied outside season of insect’s activity -0.11 -0.52 0.29 0.585 -0.26 -0.65 0.14 0.209
Interaction between studied outside season and parent’s age -0.06 -0.11 -0.01 0.012 -0.02 -0.07 0.02 0.349
VIT beginning vs. diagnosis -0.08 -0.60 0.44 0.754 -0.14 -0.65 0.37 0.582
Up to 3 yrs of VIT vs diagnosis -0.34 -0.99 0.30 0.297 -0.16 -0.68 0.36 0.556
3 yrs of VIT or longer vs diagnosis -0.46 -1.07 0.15 0.136 -0.81 -1.43 -0.18 0.011
II vs I or LLR  1.36 0.62 2.10 <0.001 -0.01 -0.57 0.54 0.960
III vs I or LLR 1.27 0.46 2.08 0.002 0.29 -0.26 0.85 0.297
IV vs I or LLR 1.50 0.69 2.32 <0.001 -0.26 -0.82 0.31 0.374
Limitations & discomfort 0.17 -0.08 0.41 0.192 0.42 0.20 0.64 <0.001
Constant 2.33 1.52 3.14 <0.001 3.00 2.31 3.69 <0.001
Table 5. Independent predictors of feeling of safety in parents of HVA children and adolescents with respect to their place of residence
Urban Rural
B 95% CI p B 95% CI p
Parents’ gender: F vs. M 0.00 -0.49 0.50 0.991 -0.16 -0.49 0.18 0.362
Child’s gender: F vs. M 0.81 0.16 1.46 0.015 -0.85 -1.51 -0.20 0.011
Interaction between parents’ gender and child’s gender 0.03 -0.66 0.72 0.941 1.05 0.25 1.84 0.010
Child’s age  -0.14 -0.20 -0.09 <0.001 0.01 -0.03 0.05 0.501
Outside season of insect’s activity -0.29 -0.65 0.06 0.107 -0.38 -0.68 -0.08 0.014
VIT beginning vs. diagnosis -0.63 -1.11 -0.15 0.010 0.51 0.13 0.88 0.008
Up to 3 yrs of VIT vs diagnosis 0.64 0.11 1.16 0.018 0.01 -0.43 0.45 0.976
3 yrs of VIT or longer vs diagnosis - - - - -0.02 -0.46 0.41 0.916
Parents’ anxiety 0.20 -0.15 0.55 0.269 -0.21 -0.43 0.01 0.059
Parents’ caution -0.52 -0.89 -0.15 0.006 -0.19 -0.41 0.02 0.074
Constant 4.08 3.20 4.96 <0.001 5.02 4.24 5.81  <0.001
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beginning of VIT reported a higher feeling of safety than 
those studied at diagnosis. Higher safety was accompanied by 
lower caution, irrespective of the place of residence, whereas 
in rural living parents, it was also accompanied by lower 
anxiety (Tab. 5).
DISCUSSION
This study presents the results of the first investigation 
concerning the QoL of parents of HV-allergic children and 
adolescents conducted with the use of PoCHVAQoLS – the 
only scale developed especially for the measurement of 
QoL in this parental group [11, 12]. The results of the study 
show that particular dimensions of the parents’ QoL are 
affected by their children’s clinical characteristics, children’s 
and parents’ demographic characteristics, as well as their 
relationship to some other dimensions of QoL (Fig. 2).
The study shows that the parents of children treated for 
a longer time reported lower anxiety than those studied at 
diagnosis or at the beginning of VIT; however, the stage of 
treatment at which this difference was observed differed 
between urban and rural-dwelling parents. This difference 
might have occurred because rural living children are at 
a greater risk of being stung, in spite of the fact that VIT-
treated children are protected against SR immediately after 
reaching the maintenance dose of treatment. In a previous 
study by the authors addressed to the parents of VIT-treated 
children aged up to 13 years they showed that there was a non-
linear relationship between the level of anxiety and treatment 
duration: the parents of children treated from half-a-year to 
2 years reported lower anxiety than the parents of children 
treated for shorter as well as for longer periods [17].
There was a gender-related difference in the slopes of 
the relationship between parental age and anxiety. These 
results, to some extent, are similar to those reported by 
Wrześniewski et  al., who showed that in a normalization 
sample drawn from the Polish general population, the anxiety 
trait, (tendency to perceive as dangerous situations which 
objectively do not pose any threat) increases along with age in 
both genders [18]. This similarity may result from the fact that 
items of PoCHVAQoLS ask for a person’s common feelings 
and behaviours concerning the occurrence of a particular 
situation, in the same way as items measuring the anxiety 
trait. Age significantly impacts parental anxiety, especially 
in those studied at the beginning of VIT. In spite of the fact 
that starting treatment of the child, which should increase 
parental safety, the incremental dose of VIT itself may result 
in systemic, sometimes life-threatening reactions. A positive 
regression coefficient for the interaction between the age of 
parents of VIT-starting children and anxiety may indicate 
that older parents are more aware of this possibility, or are 
more sceptic about VIT efficiency.
A similar relationship was observed in the case of impact 
of the child’s age on parental anxiety, which interacted with 
the stage of treatment. It seems obvious that the parents of 
older children appeared to feel safer due to having more 
independent children, what connected with the beginning 
of treatment may reduce the anxiety of the parents. However, 
in children treated for up to 3 years, the relationship between 
the child’s age and parents anxiety was the reverse, and may 
also result from the greater extent of independence presented 
by older children, as the parents have a diminished possibility 
to control them.
The relationship between anxiety, child’s age and caution 
seems to be obvious: increasing anxiety provokes the parents 
to a greater number of cautious behaviours in order to retain 
a comfortable feeling of safety, whereas as the age of the 
child increases, his/her self-responsibility also increases. 
A similar relationship concerning anxiety and caution was 
observed in Polish adolescents with HVA [19]. In previous 
studies by the authors of the current paper, performed with 
an adaptation of the Vespid Quality of Life Questionnaire 
(VQLQ) for parents of Polish children (aged up to 13 years), a 
reversed U-shaped relationship was obtained: caution was the 
lowest in parents of children aged 10 or less, and the highest 
in parents of 11-year-old children [17].
The level of limitations and discomfort of the parents was 
related to the type of culprit insect – parents of children with 
a known culprit insect had higher scores in this dimension 
than those who did not know the culprit insect. This may 
suggest that being aware of the reason for the health problems 
of the child is a greater burden that lack of this awareness. 
This was also related to the level of anxiety and caution, 
suggesting that higher anxiety about the child, its safety 
and health, may cause higher discomfort, whereas a greater 
amount of cautious behaviours may increase the feeling 
of limitations in parents. Previous studies by the authors 
provided results which, to some extent, are similar and 
showed that the discomfort of parents increased along with 
their caution [17]. A similar impact of anxiety and caution 
on limitations was also observed in Polish adolescents with 
HVA [19].
A positive correlation between support and level of 
limitations and discomfort may be interpreted as giving 
support to a child may by itself cause discomfort to parents. 
Education of the child in safety behaviours may be one of 
the coping strategies for parents to increase their personal 
comfort.
Lower support given by mothers of children treated more 
than 3 years also seems to be an obvious result, because 
children who are treated for such a long time are fully protected 
by VIT, they are also generally older, more independent, and 
do not need so much support, irrespective of the treatment 
effects. The difference between parent’s gender showed that 
the level of support given by mothers was independent of 
the severity of the child’s anaphylactic reaction, whereas the 
fathers of children with at least Mueller’s 2nd grade provided 
their children with higher support. This observation may 
result from the fact that mothers treat their children’s disease 
Figure 2. Statistically significant relationships between dimensions of QoL of 
parents of children and adolescents with HVA.
Numbers are unstandardized linear regression coefficients
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as serious, irrespective of its clinical severity, whereas fathers 
start a supportive action when the disease is confirmed by a 
doctor’s diagnosis and at the start of treatment, which usually 
refers to children with at least 2nd grade of severity of reaction.
Although the pattern of relationship between safety and 
anxiety is obvious, the direction of another relationship 
seems to be the most surprising, as one may expect that a 
higher level of feeling of safety should correspond to a higher 
level of caution. However, this result may indicate that parents 
may inhibit some cautious behaviours to increase their and/
or their children’s level of safety, therefore greater caution 
occurs as a way of compensating for the low level of safety 
feeling. The lower level of safety in parents studied outside 
the activity period of insects, observed in rural-dwellers 
may be surprising. It should be mentioned that the parents 
of diagnosed children or of those starting VIT are usually 
studied outside the season, thus, such parents are shortly after 
an experience of SR in their children, and are aware that the 
risk of a subsequent sting for their children is rather high. 
They may be afraid of such an event being repeated, or may 
expect SR as a side-effect of a VIT incremental dose.
It was observed in urban parents that the level of feeling of 
safety decreased along with the increasing age of the child, 
which may result from the potential risky behaviours in this 
age group, regardless of HVA. The relationships between 
parents’ and children’s gender compared to place of living and 
feeling of safety, may be explained by the higher availability 
of urban medical services. Despite early protection due to 
the introduction of VIT, differences among urban and rural 
inhabitants, in the feeling of safety at various stages of the 
VIT treatment, may occur due to a higher probability in the 
latter group of being stung. 
There is no possibility to compare the presented results 
with the results obtained in studies of HRQoL of adult 
patients with HVA. All such studies were conducted using 
the VQLQ scale, which contains items concerning anxiety, 
caution and discomfort; however, the authors defined the 
tool as uni-dimensional [20–28].
Limitations of the study. It should be mentioned that 
contrary to the previous studies by the authors, the current 
study did not include the parents of children who completed 
treatment, therefore it could not provide a full comparison 
of their QoL across different stages of treatment. The cross-
sectional design of the study imposes some limitations 
concerning interpretation of the relationship between stage of 
treatment and parental QoL. The lack of children treated with 
protocols other than ultra-rush also limited the possibility of 
generalizing the results, as in previous studies by the authors, 
which revealed an impact of VIT protocol on some QoL 
dimensions. It should be also noticed that the model of the 
study could be examined using structural equation modelling 
(SEM) to test the relationships between all studied variables 
simultaneously. The SEM requires a much larger sample 
sizes than that presented – in the literature it is suggested 
that it should exceed 200 [29]. In the case of rare diseases, 
such as HVA, it would be very time consuming, usually it 
is possible to include to the study 10-15 children within the 
year, which would lead to an oversampling of diagnosed 
children, with a proportionally too small representation of 
patients at different stages of treatment. A greater sample size 
would also result in a higher power of the study.
CONCLUSIONS
The longest VIT duration in children and adolescents with 
HVA is related to the decreased anxiety of their parents. 
Caution increases along with increasing anxiety, whereas 
limitations and discomfort increase along with increase of 
both these variables. The gender of the parent and severity 
grade influence the level of support given to children. In 
mothers, greater support is related to a greater level of 
limitations and discomfort. The feeling of safety of the parents 
depends on the stage of treatment and the place of residence.
Conflict of interests
The authors declare that they have no competing interests.
Acknowledgements
The authors express their thanks to Matylda Gawor for her 
critical review of the text as the English proofreader.
REFERENCES
1. Biló BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JNG, the 
EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis 
of Hymenoptera venom allergy. Allergy 2005; 60: 1339–1349.
2. Grabenhenrich LB, Dölle S, Moneret-Vautrin A, Köhli A, Lange L, 
Spindler T, et al. Anaphylaxis in children and adolescents: The European 
Anaphylaxis Registry. J Allergy Clin Immunol. 2016; 137: 1128–1137.e1.
3. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend 
M. Measuring quality of life in the parents of children with asthma. 
Qual Life Res. 1996; 5: 27–34.
4. Silva CM, Barros L, Simões F. Health-related quality of life in paediatric 
asthma: children’s and parents' perspectives. Psychol Health Med. 
2015; 8: 940–954.
5. Cianchetti C, Bianchi E, Guerrini R, Baglietto MG, Briguglio M, 
Cappelletti S, et al. Symptoms of anxiety and depression and family’s 
quality of life in children and adolescents with epilepsy. Epilepsy Behav. 
2018; 79: 146–153.
6. Gomes MC, Pinto-Sarmento TC de A, Costa EMM de B, Martins CC, 
Granville-Garcia AF, Paiva SM. Impact of oral health conditions on the 
quality of life of preschool children and their families: a cross-sectional 
study. Health Qual Life Outcomes. 2014; 12: 55.
7. Kiliś-Pstrusińska K, Medyńska A, Adamczyk P, Bałasz-Chmielewska 
I, Grenda R, Kluska-Jóźwiak A, et al. Disease-related social situation in 
family of children with chronic kidney disease – parents̀  assessment. 
A multicentre study. Ann Agric Environ Med. 2014; 21: 876–881.
8. Turan E, Kandemir H, Yeşilova Y, Ekinci S, Tanrikulu O, Kandemir SB, 
et al. Assessment of psychiatric morbidity and quality of life in children 
and adolescents with cutaneous leishmaniasis and their parents. Adv 
Dermatology Allergol. 2015; 5: 344–348.
9. Yoshihara S, Kanno N, Fukuda H, Arisaka O, Arita M, Sekine K, et al. 
Caregiver treatment satisfaction is improved together with children’s 
asthma control: Prospective study for budesonide monotherapy in 
school-aged children with uncontrolled asthma symptoms. Allergol 
Int. 2015; 64: 371–376.
10. Chernyshov P V. Gender differences in health-related and family quality 
of life in young children with atopic dermatitis. Int J Dermatol. 2012; 
51: 290–294.
11. Brzyski P, Cichocka-Jarosz E, Lis G, Tobiasz-Adamczyk B. Development 
of parents’ of children with Hymenoptera Venom Allergy Quality of Life 
Scale (PoCHVAQoLS). Adv Dermatology Allergol. 2015; 32: 143–153.
12. Brzyski P, Chichocka-Jarosz E. Parents’ of Children with Hymenoptera 
Venom Allergy Quality of Life Scale (PoCHVAQoLS) official webpage. 
http://www.pochvaqols.cm-uj.krakow.pl. (access: 2015.01.05).
13. Cichocka-Jarosz E, Brzyski P, Tobiasz-Adamczyk B, Lis G, Pietrzyk JJ. 
Development of children’s hymenoptera venom allergy quality of life 
scale (CHVAQoLS). Clinical and Translational Allergy. 2013; 3: 25.
14. Cichocka-Jarosz E, Brzyski P. Children’s Hymenoptera Venom Allergy 
Quality of Life Scale (CHVAQoLS) official webpage. www.chvaqols.
cm-uj.krakow.pl. (access: 2015.01.05).
15. Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller U, EAACI Interest 
Group on Insect Venom Hypersensitivity. Prevention and treatment of 
320
Annals of Agricultural and Environmental Medicine 2019, Vol 26, No 2
Ewa Cichocka-Jarosz, Piotr Brzyski, Izabella Tarczoń, Urszula Jedynak-Wąsowicz, Tomasz Tomasik, Grzegorz Lis. Quality of life in parents of children and adolescents…
hymenoptera venom allergy: guidelines for clinical practice. Allergy. 
2005; 60: 1459–1470.
16. Tobiasz-Adamczyk B, Brzyski P, Cichocka-Jarosz E. Jakość życia 
chorych z alergią na jad owadów [Quality of life of patients with venom 
allergy]. In: Nittner-Marszalska M, editor. Alergia na owady [Insect 
allergy]. Łódź, Mediton Oficyna Wydawnicza, 2016. p. 105–123.
17. Cichocka-Jarosz E, Tobiasz-Adamczyk B, Brzyski P, Lis G, Jedynak-
Wąsowicz U, Pietrzyk JJ, et  al. Jakość życia warunkowana stanem 
zdrowia dzieci z alergią na jad owadów błonkoskrzydłych leczonych 
VIT oraz jakość życia ich rodziców [Health-related quality of life in 
children with Hymenoptera venom allergy treated with VIT and quality 
of life of their parents]. Przegląd Lek. 2010: 12: 1243–1248.
18. Wrześniewski K, Sosnowski T, Jaworowska A, Fecenec D. Inwentarz 
Stanu i Cechy Lęku STAI. Polska adaptacja STAI. Podręcznik. 
Warszawa, Pracownia Testów Psychologicznych PTP, 2006.
19. Cichocka-Jarosz E, Brzyski P, Świebocka E, Lange J, Tobiasz-Adamczyk 
B, Lis G, et al. Health-related quality of life in Polish adolescents with 
Hymenoptera venom allergy treated with venom immunotherapy. Arch 
Med Sci. 2012; 6: 1076–1082.
20. Oude-Elberink JNG, de Konchy JGR, Golden DBK, Brouwer J-LP, 
Guyatt GH, Dubois AEJ, et al. Development and validation of a health-
related quality-of-life questionnaire in patients with yellow jacket 
allergy. J Allergy Clin Immunol. 2002; 1: 162–170.
21. Oude Elberink JNG, Dubois AEJ. Quality of life in insect venom allergic 
patients. Curr Opin Allergy Clin Immunol. 2003; 3: 287–293.
22. Niedoszytko M, Majkowicz M, Chełmińska M, Buss T, Gruchała-
Niedoszytko M, Jassem E. Quality of life, anxiety, depression 
and satisfaction with life in patients treated with insect venom 
immunotherapy. Adv Dermatology Allergol. 2012; 2: 74–79.
23. Fischer J, Feidt A, Giel KE, Martens U, Zipfel S, Biedermann T, 
Teufel M. Quality-of-life in wasp venom allergy – validation of the 
German version of the “Vespid Allergy Quality of Life Questionnaire” 
(VQLQ-d). JDDG; 2011; 9: 379–385.
24. Koschel DS, Schmies M, Nink Weber C, Höffken G, Balck F. Tolerated 
Sting Challenge in Patients on Hymenoptera Venom Immunotherapy 
Improves Health-Related Quality of Life, J Investig Allergol Clin 
Immunol. 2014; 24: 226–230.
25. Alfaya T, Vega A, Domínguez-Noche C, Ruiz B, Marqués L, Sánchez-
Morillas L. Longitudinal Validation of the Spanish Version of the 
Health-Related Quality of Life Questionnaire for Hymenoptera 
Venom Allergy (HRQLHA). J Investig Allergol Clin Immunol. 2015; 
25: 426–430.
26. Armisén M, Guspi R, Alfaya T, Cruz S, Fernández S, Domínguez-
Noche C, Alonso A, Dalmau G, Marqués L, Vega A. Cross-Sectional 
Validation of a Quality of Life Questionnaire in Spanish for Patients 
Allergic to Hymenoptera Venom. J Investig Allergol Clin Immunol. 
2015; 25: 107–111.
27. Sin BA, Öztuna D, Gelincik A, Gürlek F, Baysan A, Sin AZ, Aydın Ö, 
Mısırlıgil Z. Quality-of-life in insect venom allergy: validation of the 
Turkish version of the “Vespid Allergy Quality of Life Questionnaire” 
(VQLQ-T), Springer Plus 2016; 5: 583, DOI 10.1186/s40064-016-2246-x.
28. Silva D, Pereira AM, Santo SN, Amaral L, Delgado L, Oude Elberink 
J.N.G. (H.), Coimbra A. The Vespid Allergy Quality of Life Questionnaire 
– cultural adaptation and translation to Portuguese. Eur Ann Allergy 
Clin Immunol. 2017; 49: 114–121.
29. Schumacker RE, Lomax RG. A beginner’s guide to structural equation 
modelling, Second edition. Mhawah: Lawrence Erlbaum Associates 
2004.
321
